Cargando…
PD-1/PD-L1免疫检查点抑制剂在肺癌中的研究进展
In recent years, research on immunotherapy has made great progress. Currently, immunotherapy has made significant breakthrough, especially programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors (e.g, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab and Avelumab, etc.) have...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580087/ https://www.ncbi.nlm.nih.gov/pubmed/31196371 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.06.07 |